Drug Targeting Therapy in Multiple Myeloma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 168
Special Issue Editors
Interests: multiple myeloma; non-coding RNA
2. Division of Hematology, Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-0086, Japan
Interests: multiple myeloma; tumor microenvironment; tumor immunity; immunotherapy; immune checkpoint
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The prognosis of multiple myeloma has markedly improved due to the development and clinical use of novel agents, such as proteasome inhibitors, cereblon modulators, and antibodies, including anti-CD38 and anti-SLAMF7. However, it is still an incurable malignancy. Eventually, the disease will become resistant to all drugs; therefore, we must identify new therapeutic targets and develop new drugs. Several new therapeutic approaches, including bispecific antibodies connecting CD3+ T cells to the B cell maturation antigen (BCMA) or GPRC5D on myeloma cells, antibody drug conjugates (ADC), and chimeric antigen receptor T cell (CAR-T) therapy, are currently being developed. As the bcl-2 inhibitor, venetoclax, demonstrated good efficacy only against myeloma with t(11;14), developing drugs that target a specific type of myeloma is also a popular topic. Although some myeloma patients now live longer, myeloma has poor prognostic factors, such as adverse cytogenetics, extramedullary disease, and plasma cell leukemia. This Special Issue will cover not only new drugs and their targets, but also new therapeutic targets undergoing basic research exploration.
Dr. Hiroshi Handa
Guest Editor
Prof. Dr. Hideto Tamura
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- novel drug
- novel targets
- new therapeutic targets
- prognosis
